Lp-PLA2: A new target for statin therapy (original) (raw)

Lp-PLA2—A novel marker of atherosclerosis: To treat or not to treat?

Dimitris Tousoulis, Nikolaos Papageorgiou

International Journal of Cardiology, 2013

View PDFchevron_right

On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management

Archives of Medical Science

View PDFchevron_right

The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review

Richard Batsell

Journal of Clinical Lipidology, 2009

View PDFchevron_right

Systematic Review of the Association between Lipoprotein � Associated Phospholipase A2 and Atherosclerosis

American Chinese Journal of Medicine and Science, 2011

View PDFchevron_right

Association between Lp-PLA 2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis

Natalie Khuseyinova

Atherosclerosis, 2005

View PDFchevron_right

Lipoprotein-Associated Phospholipase A2: A Promising Vascular-Specific Marker for Screening Cardiovascular Risk?

Dr. Marguerite M Engler

Progress in Cardiovascular Nursing, 2000

View PDFchevron_right

Lipoprotein-Associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients

PLOS ONE, 2012

View PDFchevron_right

Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events

Sanja Stankovic

Current Atherosclerosis Reports, 2006

View PDFchevron_right

Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL

Κωνσταντίνος Τέλλης

View PDFchevron_right

Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study

View PDFchevron_right

Lipoprotein-Associated Phospholipase A 2 Activity Predicts Progression of Subclinical Coronary Atherosclerosis

Diabetes Technology & Therapeutics, 2011

View PDFchevron_right

Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

Peter Macfarlane

Atherosclerosis, 2010

View PDFchevron_right

Role of lipoprotein-associated phospholipase A 2 in leukocyte activation and inflammatory responses

Atherosclerosis, 2007

View PDFchevron_right

Role of Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis

Richard Batsell

Arteriosclerosis, Thrombosis, and Vascular Biology, 2005

View PDFchevron_right

Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease

Robert Rosenson

European Heart Journal, 2011

View PDFchevron_right

Lipoprotein-associated phospholipase A2 as a target of therapy

Current Opinion in Lipidology, 2005

View PDFchevron_right

The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort

Margaretha Persson

Atherosclerosis, 2007

View PDFchevron_right

Atherosclerotic Plaque Inflammation Varies Between Vascular Sites and Correlates With Response to Inhibition of Lipoprotein‐Associated Phospholipase A 2

Journal of the American Heart Association, 2015

View PDFchevron_right

Lp-PLA(2) activity and mass are associated with increased incidence of ischemic stroke - A population-based cohort study from Malmo, Sweden

Atherosclerosis, 2008

View PDFchevron_right

ASSESSMENT OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN CORONARY ARTERY DISEASE PATIENTS OF NORTH INDIA

International Journal of Bioassays

View PDFchevron_right

Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

Margaretha Persson

Arteriosclerosis, Thrombosis, and Vascular Biology, 2007

View PDFchevron_right

Discordantly elevated apolipoprotein B versus low-density lipoprotein cholesterol is associated with increased LP-PLA2 activity and poorer outcomes

Atherosclerosis, 2017

View PDFchevron_right

Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis

Κωνσταντίνος Τέλλης

View PDFchevron_right

Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target

Arteriosclerosis, Thrombosis, and Vascular Biology, 2005

View PDFchevron_right

Phospholipase A2 enzymes and the risk of atherosclerosis

Robert Rosenson

European Heart Journal, 2012

View PDFchevron_right

Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome

Atherosclerosis, 2011

View PDFchevron_right

Distribution and Correlates of Lipoprotein-Associated Phospholipase A 2 in an Elderly Cohort: The Cardiovascular Health Study

Cam Solomon, Curt Furberg

View PDFchevron_right

Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women

Estevo Santamarina

American Heart Journal, 2011

View PDFchevron_right

Lp-PLA₂, a new biomarker of vascular disorders in metabolic diseases

Liliana Mannucci

International Journal of Immunopathology and Pharmacology, 2019

View PDFchevron_right

Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults The CARDIA Study

2010

View PDFchevron_right